Literature DB >> 24531840

Rivaroxaban use following bariatric surgery.

Zachariah Thomas1, Yaron Bareket, Wendy Bennett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24531840     DOI： 10.1007/s11239-014-1057-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  9 in total

1.  Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

Authors:  Dagmar Kubitza; Michael Becka; Michael Zuehlsdorf; Wolfgang Mueck
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

2.  Obesity begets atrial fibrillation: a contemporary summary.

Authors:  Jared W Magnani; Elaine M Hylek; Caroline M Apovian
Journal:  Circulation       Date:  2013-07-23       Impact factor: 29.690

3.  Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.

Authors:  Dagmar Kubitza; Michael Becka; Michael Zuehlsdorf; Wolfgang Mueck
Journal:  J Clin Pharmacol       Date:  2007-02       Impact factor: 3.126

4.  Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.

Authors:  Adrian Mahlmann; Siegmund Gehrisch; Jan Beyer-Westendorf
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

5.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.

Authors:  E M Hylek; S J Skates; M A Sheehan; D E Singer
Journal:  N Engl J Med       Date:  1996-08-22       Impact factor: 91.245

6.  Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.

Authors:  R D Hull; G E Raskob; R F Brant; G F Pineo; K A Valentine
Journal:  Arch Intern Med       Date:  1997 Dec 8-22

7.  The effect of food on the absorption and pharmacokinetics of rivaroxaban.

Authors:  Jan Stampfuss; Dagmar Kubitza; Michael Becka; Wolfgang Mueck
Journal:  Int J Clin Pharmacol Ther       Date:  2013-07       Impact factor: 1.366

8.  Early anticoagulation is associated with reduced mortality for acute pulmonary embolism.

Authors:  Sean B Smith; Jeffrey B Geske; Jennifer M Maguire; Nicholas A Zane; Rickey E Carter; Timothy I Morgenthaler
Journal:  Chest       Date:  2010-01-15       Impact factor: 9.410

9.  Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative.

Authors:  Jonathan F Finks; Wayne J English; Arthur M Carlin; Kevin R Krause; David A Share; Mousumi Banerjee; John D Birkmeyer; Nancy J Birkmeyer
Journal:  Ann Surg       Date:  2012-06       Impact factor: 12.969
  9 in total
  2 in total

Review 1.  The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.

Authors:  Raffaele De Caterina; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2017-04-10       Impact factor: 5.460

2.  Rivaroxaban for a Patient with Class III Obesity: Case Report with Literature Review.

Authors:  Duane Bates; Jenny Edwards; Jeffrey Shrum; Casey Chan; Sharita Manga; Elizabeth MacKay
Journal:  Can J Hosp Pharm       Date:  2018-03-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.